Regeneron Pharmaceuticals (REGN) Depreciation & Amortization (CF) (2009 - 2026)

Regeneron Pharmaceuticals' Depreciation & Amortization (CF) history runs 18 years deep, the most recent figure standing at $123.7 million for Q2 2026.

• In Q2 2026, Depreciation & Amortization (CF) fell 8.44% year-over-year to $123.7 million; the TTM figure through Jun 2026 stood at $528.6 million (up 3.63% YoY), while the FY2025 annual figure was $543.7 million, up 12.59% from the prior year.
• Depreciation & Amortization (CF) for Q2 2026 stood at $123.7 million, roughly flat from $123.2 million in the prior quarter.
• The five-year high for Depreciation & Amortization (CF) was $145.0 million in Q4 2025, with the low at $74.3 million in Q1 2022.
• The 5-year median for Depreciation & Amortization (CF) is $117.4 million (2024), against an average of $113.1 million.
• The sharpest annual moves came in 2023 and 2026: Depreciation & Amortization (CF) surged 38.58% in 2023, then dropped 8.44% in 2026.
• Regeneron Pharmaceuticals' Depreciation & Amortization (CF) stood at $100.1 million in 2022, then increased by 12.89% to $113.0 million in 2023, then grew by 11.86% to $126.4 million in 2024, then grew by 14.72% to $145.0 million in 2025, then retreated by 14.69% to $123.7 million in 2026.
• Business Quant data shows REGN's Depreciation & Amortization (CF) at $123.7 million in Q2 2026, $123.2 million in Q1 2026, and $145.0 million in Q4 2025.